Search

Your search keyword '"Eich H"' showing total 389 results
Start Over Author "Eich H"
389 results on '"Eich H"'

1. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Author

Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A.S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J.U., Kobe, C., Eich, H.-T., Baues, C., Fuchs, M., Borchmann, P., and Behringer, K.

Published
2024
Full Text
View/download PDF

4. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO)

Author

Dapper, H., Belka, C., Bock, F., Budach, V., Budach, W., Christiansen, H., Debus, J., Distel, L., Dunst, J., Eckert, F., Eich, H., Eicheler, W., Engenhart-Cabillic, R., Fietkau, R., Fleischmann, D. F., Frerker, B., Giordano, F. A., Grosu, A. L., Herfarth, K., Hildebrandt, G., Kaul, D., Kölbl, O., Krause, M., Krug, D., Martin, D., Matuschek, C., Medenwald, D., Nicolay, N. H., Niewald, M., Oertel, M., Petersen, C., Pohl, F., Raabe, A., Rödel, C., Rübe, C., Schmalz, C., Schmeel, L. C., Steinmann, D., Stüben, G., Thamm, R., Vordermark, D., Vorwerk, H., Wiegel, T., Zips, D., and Combs, S. E.

Published
2022
Full Text
View/download PDF

5. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Author

Ferdinandus, J., primary, Müller, H., additional, Damaschin, C., additional, Jacob, A.S., additional, Meissner, J., additional, Krasniqi, F., additional, Mey, U., additional, Schöndube, D., additional, Thiemer, J., additional, Mathas, S., additional, Zijlstra, J., additional, Greil, R., additional, Feuring-Buske, M., additional, Markova, J., additional, Rüffer, J.U., additional, Kobe, C., additional, Eich, H.-T., additional, Baues, C., additional, Fuchs, M., additional, Borchmann, P., additional, and Behringer, K., additional

Published
2023
Full Text
View/download PDF

8. THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW

Author

Binkley, M. S., primary, Flerlage, J. E, additional, Borchmann, P., additional, Fuchs, M., additional, Hartmann, S., additional, Eich, H. T., additional, Savage, K. J., additional, Lo, A., additional, Skinnider, B., additional, Akhtar, S., additional, Rauf, M. S., additional, Maghfoor, I., additional, Pinnix, C. C., additional, Steiner, R., additional, Milgrom, S. A., additional, Vega, F., additional, Alomari, M., additional, Zhang, X., additional, Collins, G., additional, Advani, R. H., additional, Metzger, M., additional, Dickinson, M., additional, Wirth, A., additional, Tsang, R., additional, Prica, A., additional, Major, A., additional, Smith, S., additional, Hendrickson, P. G., additional, Kelsey, C. R., additional, Hopkins, D., additional, McKay, P., additional, Ng, A., additional, Koenig, J., additional, Constine, L. S., additional, Casulo, C., additional, Sakthivel, G., additional, Baron, J., additional, Plastaras, J. P., additional, Roberts, K. B., additional, Gao, S., additional, Al Kendi, J., additional, Al Rahbi, N., additional, Balogh, A., additional, Levis, M., additional, Ricardi, U., additional, Sridhar, A., additional, Torka, P., additional, Specht, L., additional, De Silva, R., additional, Shah, N., additional, Pickard, K., additional, Osborne, W., additional, Blazin, L. J., additional, Henry, M., additional, Chang, I., additional, Smith, C. M., additional, Halperin, D., additional, Miall, F., additional, Brady, J., additional, Mikhaeel, G., additional, Brennan, B., additional, Penn, A., additional, Senchenko, M. A., additional, Volchkov, E. V., additional, Reeves, M., additional, Hoppe, B., additional, Terezakis, S., additional, Talaulikar, D., additional, Della Pepa, R., additional, Picardi, M., additional, Kirova, Y., additional, Fergusson, P., additional, Northend, M., additional, Shankar, A., additional, Maurer, M. J., additional, Natkunam, Y., additional, Kelly, K. M., additional, Eichenauer, D. A., additional, and Hoppe, R. T., additional

Published
2023
Full Text
View/download PDF

13. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus

Author

Buske, C., Dreyling, M., Alvarez-Larran, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foa, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kroger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. -M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F., Hematology, Buske, C., Dreyling, M., Alvarez-Larran, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foa, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kroger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. -M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F., Universitätsklinikum Ulm - University Hospital of Ulm, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Imperial College London, Hammersmith Hospital NHS Imperial College Healthcare, Fondazione IRCCS Policlinico San Matteo [Pavia], Università degli Studi di Pavia = University of Pavia (UNIPV), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Hospitalier de Versailles André Mignot (CHV), Charité Campus Virchow-Klinikum (CVK), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Freie Universität Berlin, Humboldt University Of Berlin, Medical Oncology Unit, Dept of Medical Oncology and Hematology [Fondazione IRCCS Istituto Nazionale Tumori, Milan], Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Università degli Studi di Milano = University of Milan (UNIMI), Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), National and Kapodistrian University of Athens (NKUA), University College London Hospitals (UCLH), NHS Foundation Trust [London], The Royal Marsden, Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), IRCCS Ospedale San Raffaele [Milan, Italy], Queen Mary University of London (QMUL), Lékařská fakulta / Faculty of Medicine [University of Ostrava], Ostravská univerzita / University of Ostrava, Medizinische Universität Wien = Medical University of Vienna, Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University Hospital Hamburg-Eppendorf, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Centre hospitalier universitaire de Nantes (CHU Nantes), University Hospital Basel [Basel], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Department of Physiopatology and Transplantation, University of Milan (DEPT), Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona (UAB), Medical University of Łódź (MUL), Clínica Universidad de Navarra [Pamplona], Azienda Ospedaliero-Universitaria Careggi [Firenze] (AOUC), Università degli Studi di Firenze = University of Florence (UniFI), Jena University Hospital [Jena], Ludwig Maximilian University [Munich] (LMU), Leibniz Institute for Natural Product Research and Infection Biology (Hans Knoell Institute), Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Boehringer Ingelheim, BI, Amgen, Bristol-Myers Squibb, BMS, Pfizer, Astellas Pharma US, APUS, AstraZeneca, Bayer, Novartis, Roche, Sanofi, Gilead Sciences, Celgene, AbbVie, Meso Scale Diagnostics, MSD, Takeda Pharmaceutical Company, TPC, Janssen Pharmaceuticals, Merck KGaA, Jazz Pharmaceuticals, Deutsche Forschungsgemeinschaft, DFG, Bundesministerium für Bildung und Forschung, BMBF, Daiichi-Sankyo, José Carreras Leukämie-Stiftung, Deutsche Krebshilfe, Ipsen, The panel would like to acknowledge the work of Klizia Marinoni and Delanie Young, from the Scientific and Medical Division at ESMO, for the project coordination and editorial assistance. None declared. CB reports honoraria from Roche/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, he reports consulting or advisory role: Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis, he reports speaker's engagement: Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, he reports research funding: Roche/Genentech, Janssen, Celltrion, Merck Sharp & Dohme (MSD), Pfizer, Amgen. MD reports honoraria as Advisory Board Member of AstraZeneca, Bayer, BeiGene, Celgene, Genmab, Gilead, Incyte, Janssen, Lilly, MorphoSys, Novartis, Roche, he reports honoraria for speaker's engagement from Amgen, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Novartis, Roche, he reports institutional research grants from AbbVie, Bayer, Gilead, Celgene, Janssen, Roche. AA-L has declared no conflicts of interest. JA reports personal financial interests as advisory board and invited speaker from Incyte, advisory board from Mallinckrodt, advisory board and invited speaker from Novartis, advisory board and invited speaker from Pfizer, she reports non-financial interests as principal investigator from Incyte, principal investigator from Novartis. LA received advisory honoraria from Roche, Celgene, Janssen-Cilag, Verastem, Eusa Pharma, Incyte, ADC Therapeutics and Gilead, research support from Gilead, and travel expenses from Roche, Celgene, Janssen-Cilag, and Eusa Pharma, speakers bureau from Novartis. CB has declared no conflicts of interest. LB reports Advisory Committee activities for AbbVie, Amgen, Astellas, Bristol Myers Squibb (BMS), Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Seattle Genetics and has research support from Bayer and Jazz Pharmaceuticals. PC has declared no conflicts of interest. MGDP has declared no conflicts of interest. MD reports personal fees from Amgen, personal fees from Takeda, personal fees from Janssen, personal fees from BeiGene, personal fees from BMS, outside the submitted work. SD reports personal financial interests as advisory board, invited speaker, fellow funding, and coordinating PI from BeiGene, writing engagement from Karger, advisory board and coordinating PI from Sanofi, funding, and other from Janssen, she reports non-financial interests as advisory role at British Society for Haematology Lymphoma Special Interest Group, advisory role at Lymphoma Action, member of board of directors at WMUK Charity. HTE has declared no conflicts of interest. RF reports honoraria for advisory boards and/or speaker bureau from Janssen, Gilead, AbbVie, Amgen, Novartis, Roche, Incyte, Pfizer, all outside the submitted work. PG reports grants and personal fees from AbbVie, grants and personal fees from Acerta/AstraZeneca, personal fees from BeiGene, personal fees from Celgene/Juno/BMS, grants and personal fees from Janssen, personal fees from Lilly/Loxo, personal fees from MEI, personal fees from Roche, personal fees from Sanofi, personal fees from ArQule/MSD, outside the submitted work, MGdS reports grants, personal fees, non-financial support and other from Gilead Sciences, grants from AstraZeneca, personal fees, non-financial support, and other from Janssen Cilag, personal fees and non-financial support from Roche, non-financial support from AbbVie, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, personal fees and non-financial support from Takeda, personal fees from Novartis, personal fees from ADC Therapeutics, outside the submitted work. JG reports personal fees from AbbVie, grants and personal fees from AstraZeneca, grants and personal fees from BMS/Celgene, grants and personal fees from Janssen, personal fees from Kite/Gilead, personal fees from MorphoSys, personal fees from Novartis, personal fees from TG Therapeutics, outside the submitted work. RH has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda, has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda, has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. CH reports grants and personal fees from Novartis, grants and personal fees from BMS, personal fees from Sierra Oncology, personal fees from CTI pharmaceuticals, personal fees from Jannsen, personal fees from Geron, grants and personal fees from AOP Orphan Pharma, personal fees from Galecto, grants, personal fees and other from Constellation, outside the submitted work. MH reports personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from AbbVie, personal fees from Daiichi Sankyo, personal fees from Bayer Pharma AG, personal fees from Jazz Pharmaceuticals, personal fees from BMS, personal fees from Tolremo, outside the submitted work. BK has received honoraria for lectures from Ipsen, Novartis and MSD (all outside of the submitted work). J-JK reports consulting fees and honoraria from Novartis, consulting fees from AbbVie, honoraria from AOP Orphan Pharma, participation on a monitoring board or advisory board from BMS/Celgene, participation on a monitoring board or advisory board from Incyte. NK reports grants and honoraria from Neovii, honoraria from Sanofi, grants and honoraria from Jazz, grants and honoraria from Celgene, grants and honoraria from Riemser, honoraria from Gilead/Kite, honorarium from AOP Oprhan Pharma, grants and honorarium from Novartis, honorarium from Amgen. PM reports personal fees from Celgene, Amgen, Janssen, AbbVie, Sanofi, outside the submitted work. JP has declared no conflicts of interest. FP has declared no conflicts of interest. DR received honoraria from Incyte, Novartis Pharma, Pfizer, clinical trial steering committee membership: Novartis, membership on advisory boards: Incyte, Novartis Pharma, Pfizer. J-MR reports grants and honoraria from Novartis, Amgen, Pfizer, Takeda, Incyte, and Servier. TR has declared no conflicts of interest. JF-M reports consulting and advisory boards honoraria (received by CUN ) from AbbVie, Amgen, BMS, Celgene, Janssen, GlaxoSmithKline, Karyopharm, MSD, Novartis, Takeda, Sanofi, SecuraBio, Regeneron, Roche, outside the submitted work. VS has declared no conflicts of interest. GFS reports personal fees and other from AbbVie, other from Amgen, other from Astellas, other from Boehringer-Ingelheim, grants, personal fees and other from Celgene, other from Helsinn Healthcare, grants, personal fees, and other from Janssen-Cilag, grants and other from Novartis, other from Onconova, grants, personal fees and other from Roche, and other from Takeda, outside the submitted work. PS reports honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda, and research support from Celgene, Janssen, Amgen, Takeda, BMS, SkylineDx, Karyopharm, all outside the submitted work. MvL-T has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Pfizer, Medac, Thermo Fisher, AstraZeneca, is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4D Pharma, Janssen, Shionogi and received research funding from BMBF, Deutsche Jose Carreras Leuk?mie-Stiftung, IZKF Jena, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides, Deutsche Forschungsgemeinschaft (DFG). CW has declared no conflicts of interest. GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work. FP reports grants from Novartis, Celgene, BMS, Abbvie, Karyopharma, Janssen., MGdS reports grants, personal fees, non-financial support and other from Gilead Sciences, grants from AstraZeneca, personal fees, non-financial support, and other from Janssen Cilag, personal fees and non-financial support from Roche, non-financial support from AbbVie, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, personal fees and non-financial support from Takeda, personal fees from Novartis, personal fees from ADC Therapeutics, outside the submitted work., MvL-T has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Pfizer, Medac, Thermo Fisher, AstraZeneca, is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4D Pharma, Janssen, Shionogi and received research funding from BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides, Deutsche Forschungsgemeinschaft (DFG)., and HAL UVSQ, Équipe

Subjects
Cancer Research, Consensus, consensus manuscript, COVID-19, hematological malignancies, COVID-19, consensus manuscript, hematological malignancies, education, [SDV.CAN]Life Sciences [q-bio]/Cancer, COVID-19 Testing, Humans, Pandemics, Hematologic Neoplasms, [SDV.CAN] Life Sciences [q-bio]/Cancer, Oncology, SDG 3 - Good Health and Well-being, Original Research
Abstract

The panel would like to acknowledge the work of Klizia Marinoni and Delanie Young, from the Scientific and Medical Division at ESMO, for the project coordination and editorial assistance. None declared. CB reports honoraria from Roche/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron; he reports consulting or advisory role: Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis; he reports speaker's engagement: Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences; he reports research funding: Roche/Genentech, Janssen, Celltrion, Merck Sharp & Dohme (MSD), Pfizer, Amgen. MD reports honoraria as Advisory Board Member of AstraZeneca, Bayer, BeiGene, Celgene, Genmab, Gilead, Incyte, Janssen, Lilly, MorphoSys, Novartis, Roche; he reports honoraria for speaker's engagement from Amgen, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Novartis, Roche; he reports institutional research grants from AbbVie, Bayer, Gilead, Celgene, Janssen, Roche. AA-L has declared no conflicts of interest. JA reports personal financial interests as advisory board and invited speaker from Incyte, advisory board from Mallinckrodt, advisory board and invited speaker from Novartis, advisory board and invited speaker from Pfizer; she reports non-financial interests as principal investigator from Incyte, principal investigator from Novartis. LA received advisory honoraria from Roche, Celgene, Janssen-Cilag, Verastem, Eusa Pharma, Incyte, ADC Therapeutics and Gilead; research support from Gilead, and travel expenses from Roche, Celgene, Janssen-Cilag, and Eusa Pharma; speakers bureau from Novartis. CB has declared no conflicts of interest. LB reports Advisory Committee activities for AbbVie, Amgen, Astellas, Bristol Myers Squibb (BMS), Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Seattle Genetics and has research support from Bayer and Jazz Pharmaceuticals. PC has declared no conflicts of interest. MGDP has declared no conflicts of interest. MD reports personal fees from Amgen, personal fees from Takeda, personal fees from Janssen, personal fees from BeiGene, personal fees from BMS, outside the submitted work. SD reports personal financial interests as advisory board, invited speaker, fellow funding, and coordinating PI from BeiGene, writing engagement from Karger, advisory board and coordinating PI from Sanofi, funding, and other from Janssen; she reports non-financial interests as advisory role at British Society for Haematology Lymphoma Special Interest Group, advisory role at Lymphoma Action, member of board of directors at WMUK Charity. HTE has declared no conflicts of interest. RF reports honoraria for advisory boards and/or speaker bureau from Janssen, Gilead, AbbVie, Amgen, Novartis, Roche, Incyte, Pfizer, all outside the submitted work. PG reports grants and personal fees from AbbVie, grants and personal fees from Acerta/AstraZeneca, personal fees from BeiGene, personal fees from Celgene/Juno/BMS, grants and personal fees from Janssen, personal fees from Lilly/Loxo, personal fees from MEI, personal fees from Roche, personal fees from Sanofi, personal fees from ArQule/MSD, outside the submitted work;, MGdS reports grants, personal fees, non-financial support and other from Gilead Sciences, grants from AstraZeneca, personal fees, non-financial support, and other from Janssen Cilag, personal fees and non-financial support from Roche, non-financial support from AbbVie, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, personal fees and non-financial support from Takeda, personal fees from Novartis, personal fees from ADC Therapeutics, outside the submitted work. JG reports personal fees from AbbVie, grants and personal fees from AstraZeneca, grants and personal fees from BMS/Celgene, grants and personal fees from Janssen, personal fees from Kite/Gilead, personal fees from MorphoSys, personal fees from Novartis, personal fees from TG Therapeutics, outside the submitted work. RH has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. CH reports grants and personal fees from Novartis, grants and personal fees from BMS, personal fees from Sierra Oncology, personal fees from CTI pharmaceuticals, personal fees from Jannsen, personal fees from Geron, grants and personal fees from AOP Orphan Pharma, personal fees from Galecto, grants, personal fees and other from Constellation, outside the submitted work. MH reports personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from AbbVie, personal fees from Daiichi Sankyo, personal fees from Bayer Pharma AG, personal fees from Jazz Pharmaceuticals, personal fees from BMS, personal fees from Tolremo, outside the submitted work. BK has received honoraria for lectures from Ipsen, Novartis and MSD (all outside of the submitted work). J-JK reports consulting fees and honoraria from Novartis, consulting fees from AbbVie, honoraria from AOP Orphan Pharma, participation on a monitoring board or advisory board from BMS/Celgene, participation on a monitoring board or advisory board from Incyte. NK reports grants and honoraria from Neovii, honoraria from Sanofi, grants and honoraria from Jazz, grants and honoraria from Celgene, grants and honoraria from Riemser, honoraria from Gilead/Kite, honorarium from AOP Oprhan Pharma, grants and honorarium from Novartis, honorarium from Amgen. PM reports personal fees from Celgene, Amgen, Janssen, AbbVie, Sanofi, outside the submitted work. JP has declared no conflicts of interest. FP has declared no conflicts of interest. DR received honoraria from Incyte, Novartis Pharma, Pfizer; clinical trial steering committee membership: Novartis; membership on advisory boards: Incyte, Novartis Pharma, Pfizer. J-MR reports grants and honoraria from Novartis, Amgen, Pfizer, Takeda, Incyte, and Servier. TR has declared no conflicts of interest. JF-M reports consulting and advisory boards honoraria (received by CUN) from AbbVie, Amgen, BMS, Celgene, Janssen, GlaxoSmithKline, Karyopharm, MSD, Novartis, Takeda, Sanofi, SecuraBio, Regeneron, Roche, outside the submitted work. VS has declared no conflicts of interest. GFS reports personal fees and other from AbbVie, other from Amgen, other from Astellas, other from Boehringer-Ingelheim, grants, personal fees and other from Celgene, other from Helsinn Healthcare, grants, personal fees, and other from Janssen-Cilag, grants and other from Novartis, other from Onconova, grants, personal fees and other from Roche, and other from Takeda, outside the submitted work. PS reports honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda, and research support from Celgene, Janssen, Amgen, Takeda, BMS, SkylineDx, Karyopharm, all outside the submitted work. MvL-T has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Pfizer, Medac, Thermo Fisher, AstraZeneca; is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4D Pharma, Janssen, Shionogi and received research funding from BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides, Deutsche Forschungsgemeinschaft (DFG). CW has declared no conflicts of interest. GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work. FP reports grants from Novartis, Celgene, BMS, Abbvie, Karyopharma, Janssen. GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work. Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Published
2022

17. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations

Author

Dapper, H., Belka, C., Bock, F., Budach, V., Budach, W., Christiansen, H., Debus, J., Distel, L., Dunst, J., Eckert, F., Eich, H., Eicheler, W., Engenhart-Cabillic, R., Fietkau, R., Fleischmann, D. F., Frerker, B., Giordano, F. A., Grosu, A. L., Herfarth, K., Hildebrandt, G., Kaul, D., Kölbl, O., (0000-0003-1776-9556) Krause, M., Krug, D., Martin, D., Matuschek, C., Medenwald, D., Nicolay, N. H., Niewald, M., Oertel, M., Petersen, C., Pohl, F., Raabe, A., Rödel, C., Rübe, C., Schmalz, C., Schmeel, L. C., Steinmann, D., Stüben, G., Thamm, R., Vordermark, D., Vorwerk, H., Wiegel, T., Zips, D., Combs, S. E., Dapper, H., Belka, C., Bock, F., Budach, V., Budach, W., Christiansen, H., Debus, J., Distel, L., Dunst, J., Eckert, F., Eich, H., Eicheler, W., Engenhart-Cabillic, R., Fietkau, R., Fleischmann, D. F., Frerker, B., Giordano, F. A., Grosu, A. L., Herfarth, K., Hildebrandt, G., Kaul, D., Kölbl, O., (0000-0003-1776-9556) Krause, M., Krug, D., Martin, D., Matuschek, C., Medenwald, D., Nicolay, N. H., Niewald, M., Oertel, M., Petersen, C., Pohl, F., Raabe, A., Rödel, C., Rübe, C., Schmalz, C., Schmeel, L. C., Steinmann, D., Stüben, G., Thamm, R., Vordermark, D., Vorwerk, H., Wiegel, T., Zips, D., and Combs, S. E.

Abstract

The new Medical Licensing Regulations 2025 (Ärztliche Approbationsordnung, ÄApprO) will soon be passed by the Federal Council (Bundesrat) and will be implemented step by step by the individual faculties in the coming months. The further development of medical studies essentially involves an orientation from fact-based to competence-based learning and focuses on practical, longitudinal and interdisciplinary training. Radiation oncology and radiation therapy are important components of therapeutic oncology and are of great importance for public health, both clinically and epidemiologically, and therefore should be given appropriate attention in medical education. This report is based on a recent survey on the current state of radiation therapy teaching at university hospitals in Germany as well as the contents of the National Competence Based Learning Objectives Catalogue for Medicine 2.0 (Nationaler Kompetenzbasierter Lernzielkatalog Medizin 2.0, NKLM) and the closely related Subject Catalogue (Gegenstandskatalog, GK) of the Institute for Medical and Pharmaceutical Examination Questions (Institut für Medizinische und Pharmazeutische Prüfungsfragen, IMPP). The current recommendations of the German Society for Radiation Oncology (Deutsche Gesellschaft für Radioonkologie, DEGRO) regarding topics, scope and rationale for the establishment of radiation oncology teaching at the respective faculties are also included.

Published
2022

19. Treatment of early stage favorable and unfavorable Hodgkin lymphoma

Author

Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T., Engert, A., Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T., and Engert, A.

Abstract

Background In early stage classical Hodgkin lymphoma (cHL), reduction of treatment-associated toxicity while maintaining achieved high cure rate remains a major goal. Objectives Evidence-based development of current treatment recommendations for early stage favorable and unfavorable HL. Methods Evaluation of current randomized trials, meta-analyses, and relevant retrospective analyses with regard to tumor control, overall survival, and safety data. Results and conclusions Two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and 20 Gy involved-site radiotherapy (IS-RT) are still regarded as standard in early stage favorable HL and are also used in the older patients, unless there are contraindications. Compared to standard treatment, the (18F)fluorodeoxyglucose (FDG) positron emission tomography (PET)-based RT-approach resulted in significantly lower tumor control in the RAPID, H10, and HD16 trials and can therefore only be considered as an individual approach after weighing the benefits and risks of long-term toxicity of RT. In early stage unfavorable HL, two cycles of (escalated(e))BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) followed by two cycles of ABVD (2 + 2) result in significantly higher progression-free survival (PFS) compared to four cycles of ABVD. The HD17 trial showed that 2 + 2 additionally enables a PET-guided RT-approach without impairment of tumor control, i.e., omission of RT in those patients with negative PET after 2 + 2. Therefore, 2 + 2 + PET-guided RT is recommended as the new standard in patients <= 60 years of age. In patients older than 60 years, combined modality treatment (CMT) with two cycles of ABVD followed by two cycles of AVD and 30 Gy IS-RT is still recommended.

Published
2022

20. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foà, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kröger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F., Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foà, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kröger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., and Passamonti, F.

Abstract

Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Published
2022

27. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations

Author

Dapper, H., primary, Belka, C., additional, Bock, F., additional, Budach, V., additional, Budach, W., additional, Christiansen, H., additional, Debus, J., additional, Distel, L., additional, Dunst, J., additional, Eckert, F., additional, Eich, H., additional, Eicheler, W., additional, Engenhart-Cabillic, R., additional, Fietkau, R., additional, Fleischmann, D. F., additional, Frerker, B., additional, Giordano, F. A., additional, Grosu, A. L., additional, Herfarth, K., additional, Hildebrandt, G., additional, Kaul, D., additional, Kölbl, O., additional, Krause, M., additional, Krug, D., additional, Martin, D., additional, Matuschek, C., additional, Medenwald, D., additional, Nicolay, N. H., additional, Niewald, M., additional, Oertel, M., additional, Petersen, C., additional, Pohl, F., additional, Raabe, A., additional, Rödel, C., additional, Rübe, C., additional, Schmalz, C., additional, Schmeel, L. C., additional, Steinmann, D., additional, Stüben, G., additional, Thamm, R., additional, Vordermark, D., additional, Vorwerk, H., additional, Wiegel, T., additional, Zips, D., additional, and Combs, S. E., additional

Published
2021
Full Text
View/download PDF

29. Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients

Author

Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Müller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V., and Heinzerling, L.

Published
2015
Full Text
View/download PDF

30. HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3).

Author

Herfarth, K., Scholz, C. W., Hübel, K., Wirths, S., Buske, C., Dürig, J., Forstpointner, R., Heidegger, S., Lenz, G., König, L., Meißner, J., Höller, U., Baues, C., De‐Colle, C., Wiegel, T., Gauler, T., Li, M., Combs, S. E., Eich, H., and Sander, A.

Subjects
FOLLICULAR lymphoma, IMMUNOGLOBULIN heavy chains
Abstract

The prospective, multicentric phase II GAZAI study of the German Lymphoma Alliance (GLA) investigated the efficacy of low dose radiation therapy (2 × 2 Gy) in combination with the anti-CD20 antibody Obinutuzumab in early stage nodal FL. At week 18, metabolic CR (Deauville score (DS) <3) was seen in 46/53 patients (87%; one patient only had a CT without FDG-PET). B Introduction: b The FORT trial demonstrated a higher complete remission (CR) rate using 12 × 2 Gy compared to 2 × 2 Gy in Follicular Lymphoma (FL) (67% vs. 47%). [Extracted from the article]

Published
2023
Full Text
View/download PDF

38. V23-6-jD: Prädiktiver Einfluss unterschiedlicher histologischer Subtypen auf die lokale Kontrolle nach stereotaktischer Bestrahlung (SBRT) von Lungenmetastasen bei Patienten mit nicht-kleinzelligem Bronchialkarzinom (NSCLC) im oligo-metastasierten Stadium [Abstract]

Author

Hörner-Rieber, J., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M. J., Eich, H. T., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Herold, H.-U., Hildebrandt, G., Imhoff, D., Janssen, S., Kahl, Klaus-Henning, Klass, N. D., Krempien, R., Lautenschläger, S. F., Lohaus, F., Petersen, C., Sackerer, I., Schrade, E., Uhlmann, L., Wittig, A., and Guckenberger, M.

Subjects
ddc:610
Published
2020

39. Phytomedicines of Europe

Author

LARRY D. LAWSON, RUDOLF BAUER, Varro E. Tyler, R. Anton, B. Kuballa, Mark Blumenthal, Loren D. Israelsen, H. Wagner, H. Schilcher, G. Franz, Eckart Eich, H. W. Rauwald, G. Willuhn, M. Wichtl, R. Bauer, S. Heptinstall, D. V. C. Awang, Larry D. Lawson, Barbara Ahlemeyer, Josef Krieglstein, O. Sticher

Published
1998

41. Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group

Author

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M., Engert, A., Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M., and Engert, A.

Published
2020

42. In-vivo dosimetric analysis in total skin electron beam therapy

Author

Elsayad, K. (Khaled), Moustakis, C. (Christos), Simonsen, M. (Manuela), Bäcker, D. (Dagmar), Haverkamp, U. (Uwe), Eich, H. (Hans-Theodor), and Universitäts- und Landesbibliothek Münster

Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine, Mycosis fungoides, Total skin electron beam, lcsh:R895-920, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Dosimeter, Cutaneous lymphoma, Leukemia cutis, Dose distribution, Medicine and health, ddc:610, Original Research Article
Abstract

Background and purpose: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. Materials and methods: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. Results: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, −25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. Conclusion: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted. Keywords: Dosimeter, Cutaneous lymphoma, Leukemia cutis, Mycosis fungoides, Dose distribution, Total skin electron beam

Published
2018

45. DEGRO 2004: 10. Jahreskongress der Deutschen Gesellschaft für Radioonkologie

Author

Wendt, Thomas G., Gademann, G., Pambor, C., Grießbach, I., von Specht, H., Martin, T., Baltas, D., Kurek, R., Röddiger, S., Tunn, U. W., Zamboglou, N., Eich, H. T., Staar, S., Gossmann, A., Hansemann, K., Semrau, R., Skripnitchenko, R., Diehl, V., Müller, R.-P., Sehlen, S., Willich, N., Rühl, U., Lukas, P., Dühmke, E., Engel, K., Tabbert, E., Bolck, M., Knaack, S., Annweiler, H., Krempien, R., Hoppe, H., Harms, W., Daeuber, S., Schorr, O., Treiber, M., Debus, J., Alber, M., Paulsen, F., Birkner, M., Bakai, A., Belka, C., Budach, W., Grosser, K.-H., Kramer, R., Kober, B., Reinert, M., Schneider, P., Hertel, A., Feldmann, H., Csere, P., Hoinkis, C., Rothe, G., Zahn, P., Alheit, H., Cavanaugh, S. X., Kupelian, P., Reddy, C., Pollock, B., Fuss, M., Roeddiger, S., Dannenberg, T., Rogge, B., Drechsler, D., Herrmann, T., Alberti, W., Schwarz, R., Graefen, M., Krüll, A., Rudat, V., Huland, H., Fehr, C., Baum, C., Glocker, S., Nüsslin, F., Heil, T., Lemnitzer, H., Knips, M., Baumgart, O., Thiem, W., Kloetzer, K.-H., Hoffmann, L., Neu, B., Hültenschmidt, B., Sautter-Bihl, M.-L., Micke, O., Seegenschmiedt, M. H., Köppen, D., Klautke, G., Fietkau, R., Schultze, J., Schlichting, G., Koltze, H., Kimmig, B., Glatzel, M., Fröhlich, D., Bäsecke, S., Krauß, A., Strauß, D., Buth, K.-J., Böhme, R., Oehler, W., Bottke, D., Keilholz, U., Heufelder, K., Wiegel, T., Hinkelbein, W., Rödel, C., Papadopoulos, T., Munnes, M., Wirtz, R., Sauer, R., Rödel, F., Lubgan, D., Distel, L., Grabenbauer, G. G., Sak, A., Stüben, G., Pöttgen, C., Grehl, S., Stuschke, M., Müller, K., Pfaffendorf, C., Mayerhofer, A., Köhn, F. M., Ring, J., van Beuningen, D., Meineke, V., Neubauer, S., Keller, U., Wittlinger, M., Riesenbeck, D., Greve, B., Exeler, R., Ibrahim, M., Liebscher, C., Severin, E., Ott, O., Pötter, R., Hammer, J., Hildebrandt, G., Beckmann, M. W., Strnad, V., Fehlauer, F., Tribius, S., Bajrovic, A., Höller, U., Rades, D., Warszawski, A., Baumann, R., Madry-Gevecke, B., Karstens, J. H., Grehn, C., Hensley, F., Berns, C., Wannenmacher, M., Semrau, S., Reimer, T., Gerber, B., Ketterer, P., Koepcke, E., Hänsgen, G., Strauß, H. G., Dunst, J., Füller, J., Kalb, S., Wendt, T., Weitmann, H. D., Waldhäusl, C., Knocke, T.-H., Lamprecht, U., Classen, J., Kaulich, T. W., Aydeniz, B., Bamberg, M., Wiezorek, T., Banz, N., Salz, H., Scheithauer, M., Schwedas, M., Lutterbach, J., Bartelt, S., Frommhold, H., Lambert, J., Hornung, D., Swiderski, S., Walke, M., Siefert, A., Pöllinger, B., Krimmel, K., Schaffer, M., Koelbl, O., Bratengeier, K., Vordermark, D., Flentje, M., Hero, B., Berthold, F., Combs, S. E., Gutwein, S., Schulz-Ertner, D., van Kampen, M., Thilmann, C., Kocher, M., Kunze, S., Schild, S., Ikezaki, K., Müller, B., Sieber, R., Weiß, C., Wolf, I., Wenz, F., Weber, K.-J., Schäfer, J., Engling, A., Laufs, S., Veldwijk, M. R., Milanovic, D., Fleckenstein, K., Zeller, W., Fruehauf, S., Herskind, C., Weinmann, M., Jendrossek, V., Rübe, C., Appold, S., Kusche, S., Hölscher, T., Brüchner, K., Geyer, P., Baumann, M., Kumpf, R., Zimmermann, F., Schill, S., Geinitz, H., Nieder, C., Jeremic, B., Molls, M., Liesenfeld, S., Petrat, H., Hesselmann, S., Schäfer, U., Bruns, F., Horst, E., Wilkowski, R., Assmann, G., Nolte, A., Diebold, J., Löhrs, U., Fritz, P., Hans-Jürgen, K., Mühlnickel, W., Bach, P., Wahlers, B., Kraus, H.-J., Wulf, J., Hädinger, U., Baier, K., Krieger, T., Müller, G., Hof, H., Herfarth, K., Brunner, T., Hahn, S. M., Schreiber, F. S., Rustgi, A. K., McKenna, W. G., Bernhard, E. J., Guckenberger, M., Meyer, K., Willner, J., Schmidt, M., Kolb, M., Li, M., Gong, P., Abdollahi, A., Trinh, T., Huber, P. E., Christiansen, H., Saile, B., Neubauer-Saile, K., Tippelt, S., Rave-Fränk, M., Hermann, R. M., Dudas, J., Hess, C. F., Schmidberger, H., Ramadori, G., Andratschke, N., Price, R., Ang, K.-K., Schwarz, S., Kulka, U., Busch, M., Schlenger, L., Bohsung, J., Eichwurzel, I., Matnjani, G., Sandrock, D., Richter, M., Wurm, R., Budach, V., Feussner, A., Gellermann, J., Jordan, A., Scholz, R., Gneveckow, U., Maier-Hauff, K., Ullrich, R., Wust, P., Felix, R., Waldöfner, N., Seebass, M., Ochel, H.-J., Dani, A., Varkonyi, A., Osvath, M., Szasz, A., Messer, P. M., Blumstein, N. M., Gottfried, H.-W., Schneider, E., Reske, S. N., Röttinger, E. M., Grosu, A.-L., Franz, M., Stärk, S., Weber, W., Heintz, M., Indenkämpen, F., Beyer, T., Lübcke, W., Levegrün, S., Hayen, J., Czech, N., Mbarek, B., Köster, R., Thurmann, H., Todorovic, M., Schuchert, A., Meinertz, T., Münzel, T., Grundtke, H., Hornig, B., Hehr, T., Dilcher, C., Chan, R. C., Mintz, G. S., Kotani, J.-I., Shah, V. M., Canos, D. A., Weissman, N. J., Waksman, R., Wolfram, R., Bürger, B., Schrappe, M., Timmermann, B., Lomax, A., Goitein, G., Schuck, A., Mattke, A., Int-Veen, C., Brecht, I., Bernhard, S., Treuner, J., Koscielniak, E., Heinze, F., Kuhlen, M., von Schorlemer, I., Ahrens, S., Hunold, A., Könemann, S., Winkelmann, W., Jürgens, H., Gerstein, J., Polivka, B., Sykora, K.-W., Bremer, M., Thamm, R., Höpfner, C., Gumprecht, H., Jäger, R., Leonardi, M. A., Frank, A. M., Trappe, A. E., Lumenta, C. B., Östreicher, E., Pinsker, K., Müller, A., Fauser, C., Arnold, W., Henzel, M., Groß, M. W., Engenhart-Cabillic, R., Schüller, P., Palkovic, S., Schröder, J., Wassmann, H., Block, A., Bauer, R., Keffel, F.-W., Theophil, B., Wisser, L., Rogger, M., Niewald, M., van Lengen, V., Mathias, K., Welzel, G., Bohrer, M., Steinvorth, S., Schleußner, C., Leppert, K., Röhrig, B., Strauß, B., van Oorschot, B., Köhler, N., Anselm, R., Winzer, A., Schneider, T., Koch, U., Schönekaes, K., Mücke, R., Büntzel, J., Kisters, K., Scholz, C., Keller, M., Winkler, C., Prause, N., Busch, R., Roth, S., Haas, I., Willers, R., Schultze-Mosgau, S., Wiltfang, J., Kessler, P., Neukam, F. W., Röper, B., Nüse, N., Auer, F., Melzner, W., Geiger, M., Lotter, M., Kuhnt, T., Müller, A. C., Jirsak, N., Gernhardt, C., Schaller, H.-G., Al-Nawas, B., Klein, M. O., Ludwig, C., Körholz, J., Grötz, K. A., Huppers, K., Kunkel, M., Olschewski, T., Bajor, K., Lang, B., Lang, E., Kraus-Tiefenbacher, U., Hofheinz, R., von Gerstenberg-Helldorf, B., Willeke, F., Hochhaus, A., Roebel, M., Oertel, S., Riedl, S., Buechler, M., Foitzik, T., Ludwig, K., Klar, E., Meyer, A., Meier zu Eissen, J., Schwab, D., Meyer, T., Höcht, S., Siegmann, A., Sieker, F., Pigorsch, S., Milicic, B., Acimovic, L., Milisavljevic, S., Radosavljevic-Asic, G., Presselt, N., Baum, R. P., Treutler, D., Bonnet, R., Schmücking, M., Sammour, D., Fink, T., Ficker, J., Pradier, O., Lederer, K., Weiss, E., Hille, A., Welz, S., Sepe, S., Friedel, G., Spengler, W., Susanne, E., Kölbl, O., Hoffmann, W., Wörmann, B., Günther, A., Becker-Schiebe, M., Güttler, J., Schul, C., Nitsche, M., Körner, M. K., Oppenkowski, R., Guntrum, F., Malaimare, L., Raub, M., Schöfl, C., Averbeck, T., Hacker, I., Blank, H., Böhme, C., Imhoff, D., Eberlein, K., Weidauer, S., Böttcher, H. D., Edler, L., Tatagiba, M., Molina, H., Ostertag, C., Milker-Zabel, S., Zabel, A., Schlegel, W., Hartmann, A., Wildfang, I., Kleinert, G., Hamm, K., Reuschel, W., Wehrmann, R., Kneschaurek, P., Münter, M. W., Nikoghosyan, A., Didinger, B., Nill, S., Rhein, B., Küstner, D., Schalldach, U., Eßer, D., Göbel, H., Wördehoff, H., Pachmann, S., Hollenhorst, H., Dederer, K., Evers, C., Lamprecht, J., Dastbaz, A., Schick, B., Fleckenstein, J., Plinkert, P. K., Rübe, Chr., Merz, T., Sommer, B., Mencl, A., Ghilescu, V., Astner, S., Martin, A., Momm, F., Volegova-Neher, N. J., Schulte-Mönting, J., Guttenberger, R., Buchali, A., Blank, E., Sidow, D., Huhnt, W., Gorbatov, T., Heinecke, A., Beckmann, G., Bentia, A.-M., Schmitz, H., Spahn, U., Heyl, V., Prott, P.-J., Galalae, R., Schneider, R., Voith, C., Scheda, A., Hermann, B., Bauer, L., Melchert, F., Kröger, N., Grüneisen, A., Jänicke, F., Zander, A., Zuna, I., Schlöcker, I., Wagner, K., John, E., Dörk, T., Lochhas, G., Houf, M., Lorenz, D., Link, K.-H., Prott, F.-J., Thoma, M., Schauer, R., Heinemann, V., Romano, M., Reiner, M., Quanz, A., Oppitz, U., Bahrehmand, R., Tine, M., Naszaly, A., Patonay, P., Mayer, Á., Markert, K., Mai, S.-K., Lohr, F., Dobler, B., Pinkawa, M., Fischedick, K., Treusacher, P., Cengiz, D., Mager, R., Borchers, H., Jakse, G., Eble, M. J., Asadpour, B., Krenkel, B., Holy, R., Kaplan, Y., Block, T., Czempiel, H., Haverkamp, U., Prümer, B., Christian, T., Benkel, P., Weber, C., Gruber, S., Reimann, P., Blumberg, J., Krause, K., Fischedick, A.-R., Kaube, K., Steckler, K., Henzel, B., Licht, N., Loch, T., Krystek, A., Lilienthal, A., Alfia, H., Claßen, J., Spillner, P., Knutzen, B., Souchon, R., Schulz, I., Grüschow, K., Küchenmeister, U., Vogel, H., Wolff, D., Ramm, U., Licner, J., Rudolf, F., Moog, J., Rahl, C. G., Mose, S., Vorwerk, H., Weiß, E., Engert, A., Seufert, I., Schwab, F., Dahlke, J., Zabelina, T., Krüger, W., Kabisch, H., Platz, V., Wolf, J., Pfistner, B., Stieltjes, B., Wilhelm, T., Schmuecking, M., Junker, K., Treutier, D., Schneider, C. P., Leonhardi, J., Niesen, A., Hoeffken, K., Schmidt, A., Mueller, K.-M., Schmid, I., Lehmann, K., Blumstein, C. G., Kreienberg, R., Freudenberg, L., Kühl, H., Stahl, M., Elo, B., Erichsen, P., Stattaus, H., Welzel, T., Mende, U., Heiland, S., Salter, B. J., Schmid, R., Stratakis, D., Huber, R. M., Haferanke, J., Zöller, N., Henke, M., Lorenzen, J., Grzyska, B., Kuhlmey, A., Adam, G., Hamelmann, V., Bölling, T., Job, H., Panke, J. E., Feyer, P., Püttmann, S., Siekmeyer, B., Jung, H., Gagel, B., Militz, U., Piroth, M., Schmachtenberg, A., Hoelscher, T., Verfaillie, C., Kaminski, B., Lücke, E., Mörtel, H., Eyrich, W., Fritsch, M., Georgi, J.-C., Plathow, C., Zieher, H., Kiessling, F., Peschke, P., Kauczor, H.-U., Licher, J., Schneider, O., Henschler, R., Seidel, C., Kolkmeyer, A., Nguyen, T. P., Janke, K., Michaelis, M., Bischof, M., Stoffregen, C., Lipson, K., Weber, K., Ehemann, V., Jürgen, D., Achanta, P., Thompson, K., Martinez, J. L., Körschgen, T., Pakala, R., Pinnow, E., Hellinga, D., O’Tio, F., Katzer, A., Kaffer, A., Kuechler, A., Steinkirchner, S., Dettmar, N., Cordes, N., Frick, S., Kappler, M., Taubert, H., Bartel, F., Schmidt, H., Bache, M., Frühauf, S., Wenk, T., Litzenberger, K., Erren, M., van Valen, F., Liu, L., Yang, K., Palm, J., Püsken, M., Behe, M., Behr, T. M., Marini, P., Johne, A., Claussen, U., Liehr, T., Steil, V., Moustakis, C., Griessbach, I., Oettel, A., Schaal, C., Reinhold, M., Strasssmann, G., Braun, I., Vacha, P., Richter, D., Osterham, T., Wolf, P., Guenther, G., Miemietz, M., Lazaridis, E. A., Forthuber, B., Sure, M., Klein, J., Saleske, H., Riedel, T., Hirnle, P., Horstmann, G., Schoepgens, H., Van Eck, A., Bundschuh, O., Van Oosterhut, A., Xydis, K., Theodorou, K., Kappas, C., Zurheide, J., Fridtjof, N., Ganswindt, U., Weidner, N., Buchgeister, M., Weigel, B., Müller, S. B., Glashörster, M., Weining, C., Hentschel, B., Sauer, O. A., Kleen, W., Beck, J., Lehmann, D., Ley, S., Fink, C., Puderbach, M., Hosch, W., Schmähl, A., Jung, K., Stoßberg, A., Rolf, E., Damrau, M., Oetzel, D., Maurer, U., Maurer, G., Lang, K., Zumbe, J., Hahm, D., Fees, H., Robrandt, B., Melcher, U., Niemeyer, M., Mondry, A., Kanellopoulos-Niemeyer, V., Karle, H., Jacob-Heutmann, D., Born, C., Mohr, W., Kutzner, J., Thelen, M., Schiebe, M., Pinkert, U., Piasswilm, L., Pohl, F., Garbe, S., Wolf, K., Nour, Y., Barwig, P., Trog, D., Schäfer, C., Herbst, M., Dietl, B., Cartes, M., Schroeder, F., Sigingan-Tek, G., Feierabend, R., Theden, S., Schlieck, A., Gotthardt, M., Glowalla, U., Kremp, S., Hamid, O., Riefenstahl, N., Michaelis, B., Schaal, G., Liebermeister, E., Niewöhner-Desbordes, U., Kowalski, M., Franz, N., Stahl, W., Baumbach, C., Thale, J., Wagner, W., Justus, B., Huston, A. L., Seaborn, R., Rai, P., Rha, S.-W., Sakas, G., Wesarg, S., Zogal, P., Schwald, B., Seibert, H., Berndt-Skorka, R., Seifert, G., Schoenekaes, K., Bilecen, C., Ito, W., Matschuck, G., and Isik, D.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results